RecruitingPhase 2NCT07249463

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

Studying Cryptosporidiosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Intervention: Cryptosporidium parvum oocysts (ABO809)(biological)
Enrollment: 96 enrolled
Eligibility: 18-50 years · All sexes
Timeline: 2025 – 2027

Study locations (1)

Pharmaron Inc, Baltimore, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07249463 on ClinicalTrials.gov

Other trials for Cryptosporidiosis

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07388615
The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Al-Azhar University
ACTIVE NOT RECRUITINGNCT02764918
Cryptosporidiosis and Enteropathogens in Bangladesh
University of Virginia

See all trials for Cryptosporidiosis →

← Back to all trials